In an era marked by remarkable advancements, the inhalation therapy field is rapidly evolving. From Avalyn's $175 million investment in inhaled pulmonary fibrosis trials to Krystal Biotech's FDA clearance for inhaled gene therapy and MIT engineers' work on inhaled nanoparticles, the field is abuzz with new advances and breakthroughs in inhalation delivery.  

Right now, we explore inhaled therapies as an opportunity to re-purpose modalities to tackle unmet clinical need in diseases like COPD, asthma, IPF, emphysema, and lung cancer, to unlock therapeutic efficacy. Now is the time for the industry to unite and innovate solutions to challenges surrounding particle engineering, stability, and formulation-device compatibility. Immerse yourself in a wealth of knowledge at the 2nd Next Gen Inhalation Delivery Summit, as the only forum offering cutting edge, future focused updates for inhaled delivery of complex biologics, maintaining formulation integrity to achieve precise lung delivery.  

This is the premier forum dedicated to inhalation's future, providing crucial insights and networking opportunities. Join us in June to stay ahead in optimizing lung-specific drug delivery for maximum efficacy and potency in non-invasive, localized delivery.